Breaks Categories: News

ThursdayJan 19, 2023 11:23 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Spotlighted in InvestmentPitch Media Video Discussing Clinical Trial Application

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is front and center in a recent InvestmentPitch Media Video. The video spotlighted FDS Pharma’s recent submission of its clinical trial application for an upcoming phase a trial evaluating Lucid-MS. A candidate for treatment of multiple sclerosis (“MS”), Lucid-MS is a first-in-class neuroprotective compound featuring a novel mechanism action that has been shown to prevent myelin degradation, or demyelination, a significant cause of MS and other neurodegenerative diseases. According to the announcement, Lucid-MS…

Continue Reading

WednesdayJan 18, 2023 1:36 pm

BioMedNewsBreaks – MetAlert Inc.’s (MLRT) Acquisition Target’s SafetyNet(R) Makes News in Finding Missing Woman

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, last week announced that it offered $4.5 million in a cash and stock deal to acquire TrakTec, a location-awareness technology company. Expected to close on or before March 17, 2023, the acquisition will include TrakTec’s active paying subscriber base, police department contracts, commercial ready tracking products, and backend platform and mobile app. TrakTec offers affordable, scalable location-awareness technology solutions and operates iGPS Watches and SafetyNet(R) Tracking Systems that provide a range of enhanced monitoring services. These important services were demonstrated recently, as TrakTec’s SafetyNet system made…

Continue Reading

WednesdayJan 18, 2023 10:36 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Promising Results from Kernel Flow(R) Feasibility Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced key highlights from the completed feasibility study conducted by its partner HI, LLC dba Kernel (“Kernel”). The study was designed to evaluate Kernel’s Flow(R) wearable technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. “The results from the feasibility study are very promising and provide further insights into the potential of this cutting-edge wearable technology to quantify neural activity and changes in brain biomarkers during the administration of psychedelics. The possibility of using this technology to develop a predictive tool to aid…

Continue Reading

TuesdayJan 17, 2023 12:04 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Submits Phase-1 Clinical Trial Application for Lucid-MS

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced its submission of a Clinical Trial Application (“CTA”) for a planned phase-1 clinical trial for Lucid-MS, a candidate for the treatment of multiple sclerosis (“MS”). “This is an exciting time for our company, shareholders and, most importantly, for the MS community,” said Dr. Lakshmi Kotra, CEO of Lucid Psycheceuticals, a wholly owned subsidiary of FSD Pharma. “Multiple sclerosis is a debilitating disease without any cure, relegating patients and caregivers to…

Continue Reading

TuesdayJan 17, 2023 11:49 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Among First of Nasdaq Companies to Dual List on Upstream

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, last week became the second NASDAQ company to dual list on Upstream under the ticker symbol JUPW. Jupiter Wellness released a digital collectible NFT to commemorate the dual listing, which is available for all Upstream participants to claim with the code “JUPW.” “We are thrilled to be among the first companies to dual list on Upstream’s next generation marketplace,” said Jupiter Wellness CEO Brian John. “We are adding new value to our shareholders while expanding our company and mission to a modern, global investor-base.” To view the…

Continue Reading

FridayJan 13, 2023 12:01 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Authorized Share Repurchase Program

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced a share repurchase program. The company’s board of directors approved the repurchase under a normal course issuer bid; the bid is comprised of up to 1,925,210 of HUGE subordinate class B voting shares over the next 12 months at prevailing market prices. The program will enable the company to use excess cash reserves in strategic ways designed to return value to shareholders. “FSD Pharma is focused on the advancement of…

Continue Reading

FridayJan 13, 2023 10:32 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) CEO Reports on Company Accomplishments, Outlook through Shareholder Letter

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, is in an ideal position to be “profitable” in 2023. That was the outlook reported in a shareholder letter released by JUPW CEO Brian John. The letter noted 2022 highlights, such as the company becoming the second U.S. equity to dual list on Upstream, a revolutionary trading app for digital securities and NFTs, and JUPW’s SRM Entertainment division submitting a confidential registration statement to the SEC on a key step on its journey to becoming an independently traded NASDAQ company. The letter also noted that Jupiter Wellness…

Continue Reading

ThursdayJan 12, 2023 1:11 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Be Evaluated in Investigator-Initiated Phase 1b/2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced an investigator-initiated phase 1b /2 trial evaluating the company’s novel anthracycline, Berubicin. The study, titled “Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas,” will be conducted at the Pomeranian Medical University (“PUM”) in Szczecin, Poland. “Based on the data seen to date, Berubicin has continued to demonstrate an overall safety profile more favorable than other known anthracyclines and we remain encouraged by its potential.…

Continue Reading

ThursdayJan 12, 2023 10:51 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) CEO Featured in Traders News Source Interview

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, was featured in a new C-level interview with Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies. Branislav Vajdic, PhD, CEO and founder of HeartBeam joined Traders News Source’s Toni Loudenbeck to provide an overview of HeartBeam and discuss the potential for the company’s innovative AIMI(TM) and AIMIGo(TM) technology. In the interview, Dr. Vajdic shares his background and vision leading up to the company’s 12-lead standard…

Continue Reading

ThursdayJan 12, 2023 10:35 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Selects Generalized Anxiety Disorder as Target Indication for CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(R). The company today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”) as the target indication for CYB004 — its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule. “Based on preclinical data, CYB004 has shown promise in treating anxiety disorders. About half of people suffering from depression are also burdened with GAD, which makes the need for more effective treatment options for GAD even more urgent,” said Cybin CEO Doug Drysdale. “Since the pandemic, the prevalence of depression and…

Continue Reading